The data herein supports the possibility of using c-ABL as a target against DENV infection, thus suggesting that imatinib, a specific c-ABL inhibitor used in therapy for BCR-ABL-positive leukemia, could be repositioned as a host-targeted antiviral (HTA) to treat Dengue. The gene discussed is ABL1; the disease is dengue disease.